Compositions and methods for treating inflammasome related diseases or conditions

Inventors

KEANE, ROBERT W. • Dietrich, W. Dalton • De Rivero Vaccari, Juan Pablo • Bramlett, Helen M. • BRAMBILLA, Roberta

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Assignees

Member
University of Miami
University of Miami

The University of Miami, established in 1925 and based in Coral Gables, Florida, is a private research university recognized for its comprehensive academic offerings, robust research infrastructure, and strong interdisciplinary focus. Home to more than 19,000 students and with more than 400 acres of campuses across the Miami region, its mission encompasses education, research, innovation, and community service. The institution supports clinical, biomedical, marine, and atmospheric research initiatives, delivers diverse undergraduate and graduate programs, and maintains numerous research centers and institutes dedicated to scientific, medical, and societal advancements.

Publication Number

US-12570735-B2

Patent

Publication Date

2026-03-10

Expiration Date


Abstract

The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating inflammasome related diseases or conditions.

Core Innovation

The invention relates to treating inflammation in a subject by administering a therapeutically effective amount of a monoclonal antibody or an antibody fragment thereof that binds specifically to ASC (Apoptosis-associated Speck-like protein containing a Caspase Activating Recruitment Domain). The antibody or antibody fragment comprises a heavy chain variable (VH) region and a light chain variable (VL) region, with the VH region amino acid sequence comprising HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8, and the VL region amino acid sequence comprising LCDR1 of SEQ ID NO: 12, LCDR2 of SEQ ID NO: 13, and LCDR3 of SEQ ID NO: 14.

The anti-ASC antibodies and antibody fragments target ASC in the context of inflammation, including inflammasome-related inflammation, innate inflammation, and inflammasome pathways connected with ASC, including NLRP1/AIM2/ASC. The disclosure includes inflammatory settings in organs and disease contexts including lungs and the central nervous system (CNS), as well as inflammatory settings associated with CNS injury such as traumatic brain injury (TBI), spinal cord injury (SCI), and stroke.

The described inflammatory outcomes include suppression of inflammasome activation and reductions in inflammatory cytokine and inflammation metrics. Reported downstream effects include reduced inflammatory cytokines such as IL-1β and IL-18, reduced caspase-1 activation, inhibition of pyroptosis associated with gasdermin D (GSDMD) cleavage, reduced acute lung injury, and reduced neutrophil infiltration.

Claims Coverage

The provided claim set includes one independent claim. The independent claim centers on a method of treating inflammation by administering an anti-ASC monoclonal antibody or antibody fragment having specified VH and VL CDR amino acid sequence identities, with additional refinements to sequence definitions, human ASC protein, fragment formats, and treatment outcomes.

ASC-specific monoclonal antibody with defined VH and VL CDRs

A method of treating inflammation in a subject by administering a therapeutically effective amount of a monoclonal antibody or an antibody fragment that binds specifically to ASC, wherein the antibody comprises a VH region and a VL region with HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, HCDR3 of SEQ ID NO: 8, and LCDR1 of SEQ ID NO: 12, LCDR2 of SEQ ID NO: 13, and LCDR3 of SEQ ID NO: 14.

Anti-ASC method using alternative VH and VL variable region sequence identities

The method is defined by antibodies whose VH region amino acid sequence comprises SEQ ID NO: 18, 19, 20, 21, or 22 and whose VL region amino acid sequence comprises SEQ ID NO: 28, 29, 30, or 31.

Human ASC targeting

The method is performed using an ASC that is human ASC protein.

Defined antibody fragment formats

The method is performed using an antibody fragment selected from Fab, F(ab')2, Fab', scFv, a single domain antibody, a diabody, or a single chain camelid antibody.

Inflammatory cytokine reduction as a treatment outcome

Administration of the monoclonal antibody or antibody fragment is configured to reduce levels of at least one inflammatory cytokine.

Inflammasome activation inhibition

Administration results in inhibition of inflammasome activation in the subject.

The inventive coverage centers on ASC-specific monoclonal antibodies and antibody fragments defined by VH and VL CDR sequences, with further claim support for alternative VH/VL sequence options, human ASC targeting, particular antibody fragment formats, and treatment outcomes involving inflammatory cytokine reduction and inhibition of inflammasome activation.

Stated Advantages

Treats inflammation in a subject.

Reduces levels of at least one inflammatory cytokine.

Inhibits inflammasome activation in the subject.

Documented Applications

Treating inflammation associated with inflammasome activation in the central nervous system, including CNS injuries/conditions such as TBI, stroke, SCI, and diseases such as MS, ALS, AD, and PD.

Treating inflammation associated with ASC-related inflammasome activation in lungs, including acute lung injury from TBI.

Acute lung injury (ALI) settings with associated inflammation metrics, including neutrophil infiltration.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.